Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18173799 | 0.79 | HDAC8 (0.41) | DGAT1LPLLIPGANPEPLAP3 | |
| SCHEMBL21194009 | 0.78 | FFAR1 (0.36) | P2RX7LPLLIPG | |
| SCHEMBL31469268 | 0.76 | LPL (0.40) | CYP11B2HSP90AA1HSP90AB1DGAT1LPL | |
| SCHEMBL19260099 | 0.75 | P2RX7 (0.41) | P2RX7DGAT1LPLLIPGANPEP | |
| SCHEMBL29801156 | 0.72 | DYRK1A (0.55) | ANPEPLAP3 | |
| SCHEMBL14857683 | 0.72 | DYRK1A (0.55) | ANPEPLAP3 | |
| SCHEMBL3282058 | 0.72 | FFAR1 (0.35) | IDO1P2RX7LPLLIPG | |
| SCHEMBL6496747 | 0.71 | CYP11B1 (0.63) | CYP11B2CYP11B1IDO1HPGDSP2RX7 | |
| SCHEMBL6502454 | 0.71 | CYP11B1 (0.61) | CYP11B2CYP11B1IDO1HPGDSP2RX7 | |
| SCHEMBL98814 | 0.71 | FFAR1 (0.56) | DGAT1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-20 | — | — | US | disclosed |
| CN-110204544-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-110256427-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-3395818-B1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma AG (DE) | 2021-09-22 | — | — | EP | disclosed |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-12-10 | — | — | US | disclosed |
| US-10772893-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-15 | — | — | US | disclosed |
| EP-3507281-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202799-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| EP-3395818-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-31 | — | — | EP | disclosed |
| US-20180256591-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| WO-2018041964-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-03-08 | — | — | WO | disclosed |
| US-20170216304-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | disclosed |
| EP-3177619-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2017-06-14 | — | — | EP | disclosed |
| US-9549932-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-24 | — | — | US | disclosed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | disclosed |
| US-7709654-B2 | Process for producing oxazole, imidazole, pyrrazole boryl compounds | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709654-B2 | Process for producing oxazole, imidazole, pyrrazole boryl compounds | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709654-B2 | Process for producing oxazole, imidazole, pyrrazole boryl compounds | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080091027-A1 | Process for producing oxazole, imidazole, pyrrazole boryl compounds | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091027-A1 | Process for producing oxazole, imidazole, pyrrazole boryl compounds | OXA1L, ZC3HAV1L, PBK | CYP11B2 390/4885CYP11B1 408/4885IDO1 517/4885 |
| US-20190202799-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | BRD4, BRPF3, BRD3 | CYP11B2 3217/4885CYP11B1 2425/4885IDO1 185/4885 |
| US-20180256591-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | CYP11B2 212/4885CYP11B1 371/4885IDO1 1623/4885 |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | CYP11B2 212/4885CYP11B1 371/4885IDO1 1623/4885 |
| US-20170216304-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | CYP11B2 212/4885CYP11B1 371/4885IDO1 1623/4885 |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | CYP11B2 212/4885CYP11B1 371/4885IDO1 1623/4885 |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | CYP11B2 212/4885CYP11B1 371/4885IDO1 1623/4885 |
| US-10772893-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | CYP11B2 212/4885CYP11B1 371/4885IDO1 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.